BTIG analyst Robert Hazlett maintained a Buy rating on Eiger Biopharmaceuticals (EIGR – Research Report) yesterday and set a price target of $48.00. The company’s shares closed yesterday at $6.04.
Hazlett covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Eiger Biopharmaceuticals, and Homology Medicines. According to TipRanks, Hazlett has an average return of 3.3% and a 38.32% success rate on recommended stocks.
Currently, the analyst consensus on Eiger Biopharmaceuticals is a Strong Buy with an average price target of $35.00, implying a 479.47% upside from current levels. In a report released yesterday, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $28.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Eiger Biopharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $4.09 million and a GAAP net loss of $21.88 million. In comparison, last year the company earned a revenue of $2.1 million and had a GAAP net loss of $19.17 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. The company was founded by David A. Cory on November 6, 2008 and is headquartered in Palo Alto, CA.
Read More on EIGR:
- AFCP’s Belgium Subsidiary, Fuel Cell Power NV, Achieves ISO 9001:2015 Quality Management System Certification
- SVB Securities Sticks to Their Hold Rating for Adaptimmune Therapeutics (ADAP)
- SVB Securities Sticks to Its Buy Rating for Immatics (IMTX)
- Australian Stock Market Today – Wednesday, September 7: What You Need to Know
- Why Zoom Video Stock (NASDAQ:ZM) May Still be Too Expensive